Globus Medical cuts 2026 revenue outlook to $3.09B
The repurchase program has no time limit and may be suspended for periods or discontinued at any time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Globus Medical (GMED) reported third-quarter 2026 net sales of $763.7 million, down 0.7% year over year, while GAAP net income rose 18.7% to $141.2 million and diluted EPS increased 18.2% to $1.04. Non-GAAP diluted EPS was $1.23, up 4.4%; base business sales excluding Nevro were $690.0 million, up 3.0%. International sales fell 5.7%, while Enabling Technologies revenue grew 24% and robot and navigation unit deployments were 73% higher than in the prior-year quarter.
For the first nine months of 2026, net sales grew 9.5%. Globus lowered full-year 2026 revenue guidance to $3.09 billion from its previous range of $3.18 billion to $3.22 billion, while reaffirming non-GAAP fully diluted EPS guidance of $4.95 to $5.05. On November 2, the board authorized an additional $500 million in repurchases; approximately $611.0 million remained available as of that date. Management will determine the timing and number of shares repurchased at its discretion, and the program has no time limit.
2 points · 0 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointGAAP net income rose 18.7% to $141.2 million in Q3 2026.
- Moderate pointNine-month net sales grew 9.5% year over year through September 30, 2026.
Negative
- Moderate pointInternational net sales declined 5.7% year over year in Q3 2026.
8-K Event Classification
3 items: 2.02, 8.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Third-quarter net sales: $763.7 million
GAAP net income: $141.2 million
GAAP diluted EPS: $1.04 per share
+5 more
8 metrics
Third-quarter net sales
$763.7 million
Three months ended September 30, 2026; down 0.7% year over year
GAAP net income
$141.2 million
Third quarter 2026; up 18.7% year over year
GAAP diluted EPS
$1.04 per share
Third quarter 2026; up 18.2% year over year
Non-GAAP diluted EPS
$1.23 per share
Third quarter 2026; up 4.4% year over year
2026 revenue guidance
$3.09 billion
Updated from the previous range of $3.18 billion to $3.22 billion
2026 non-GAAP fully diluted EPS guidance
$4.95 to $5.05
Reaffirmed; represents 24.4% to 26.9% growth over fiscal 2025
Additional share repurchase authorization
$500 million
Authorized November 2, 2026
Repurchase program amount available
Approximately $611.0 million
As of November 2, 2026
Key Terms
Non-GAAP diluted EPS, constant currency net sales growth, Adjusted EBITDA, free cash flow
4 terms
Non-GAAP diluted EPS financial
"Non-GAAP diluted EPS was $1.23 in the third quarter of 2026"
Non-GAAP diluted EPS (Earnings Per Share) is a measure of a company's profit allocated to each share of stock, calculated using adjusted earnings that exclude certain items like one-time expenses or gains. It provides a view of ongoing performance by removing irregular or non-recurring factors. Investors use it to better understand the company's core profitability and compare performance across different periods or companies.
constant currency net sales growth financial
"constant currency net sales growth is calculated by translating current year net sales"
Adjusted EBITDA financial
"Non-GAAP Adjusted EBITDA"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
free cash flow financial
"the non-GAAP measure of free cash flow as the net cash provided by operating activities"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
Earnings Snapshot
Net sales: $763.7 million · Guidance included
Third quarter ended September 30, 2026
Net sales
$763.7 million
-0.7% year over year
GAAP net income
$141.2 million
+18.7% year over year
GAAP diluted EPS
$1.04 per share
+18.2% year over year
Non-GAAP diluted EPS
$1.23 per share
+4.4% year over year
Full-year 2026 revenue guidance
$3.09 billion
Updated from the previous range of $3.18 billion to $3.22 billion
Guidance
Full-year 2026 non-GAAP fully diluted EPS guidance was reaffirmed at $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were GMED's third-quarter 2026 sales and earnings?
Worldwide third-quarter net sales were $763.7 million, down 0.7% year over year. GAAP net income was $141.2 million, and diluted EPS was $1.04, up 18.2% from the prior-year quarter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2026
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition.
On November 5, 2026, Globus Medical, Inc. (the “Company”) issued a press release reporting, among other things, its sales and operating results for the three and nine month period ended September 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibit attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On November 2, 2026, (the “Repurchase Program Increase Date”), the Company’s Board of Directors authorized the Company to repurchase an additional $500.0 million of its Class A common stock under its existing share repurchase program (the “Repurchase Program Increase”). Following the Repurchase Program Increase, approximately $611.0 million remained available for future share repurchases under the Company’s repurchase program as of the Repurchase Program Increase Date. The timing and actual number of shares repurchased under the repurchase program will be determined by management at its discretion and will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements, and alternative investment opportunities. Repurchases may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Act. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press Release dated November 5, 2026 | |||||||
| 104 | The cover page from this Current Report on Form 8-K, formatted as Inline XBRL. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GLOBUS MEDICAL, INC. | ||||||||
| (Registrant) | ||||||||
| Dated: | November 5, 2026 | /s/ KYLE R. KLINE | ||||||
Kyle R. Kline | ||||||||
| Chief Financial Officer | ||||||||
| (Principal Financial Officer) | ||||||||
| Senior Vice President | ||||||||
Exhibit 99.1
Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program
AUDUBON, PA., November 5, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Results
•Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of 0.5% on a constant currency basis.
•Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an increase of 3.0%, as reported.
•GAAP net income for the quarter was $141.2 million.
•GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. Non-GAAP diluted EPS was $1.23, an increase of 4.4%.
•GAAP gross profit as a percentage of net sales was 66.7%, an increase of 2.5%. Non-GAAP adjusted Gross Profit as a percentage of sales was 69.5%, an increase of 1.4%.
“Third quarter revenue finished at $764 million, down slightly from the prior year quarter,” commented Keith Pfeil, President and Chief Executive Officer. “U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter. On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation. Our Enabling Technologies strategy continued to make progress, delivering revenue growth of 24%, while simultaneously deploying 73% more robot and navigation units as compared to the prior year quarter, reflecting continued strong demand for our technology and execution against our capital deployment plan. We remain focused on our long-term strategy of achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence ecosystem.”
“Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation,” said Kyle Kline, Chief Financial Officer. “Our performance reflects disciplined execution across the business, which positions us to deliver sustained earnings growth, cash generation, and enhanced shareholder returns. To further this commitment, our Board has authorized a $500 million increase to our existing share repurchase program, which reflects confidence in our long-term growth profile and underlying earnings and cash generation prowess.”
Worldwide net sales for the third quarter of 2026 were $763.7 million, an as-reported decrease of 0.7% over the third quarter of 2025. U.S. net sales for the third quarter of 2026 increased by 0.5% compared to the third quarter of 2025. International net sales decreased by 5.7% over the third quarter of 2025 on an as-reported basis and decreased by 5.0% on a constant currency basis.
GAAP net income for the third quarter of 2026 was $141.2 million, an increase of 18.7% over the same period in the prior year. The increase in GAAP net income was primarily driven by the decrease in cost of sales and operating expenses, decreasing $19.6 million and $25.9 million, respectively, in comparison to the third quarter of 2025. GAAP diluted EPS for the third quarter was $1.04, compared to $0.88 for the third quarter of 2025, an increase of 18.2%. Non-GAAP diluted EPS for the third quarter of 2026, which excludes, among other costs, amortization of intangibles, merger and acquisition-related costs, and restructuring-related costs, was $1.23, compared to $1.18 in the third quarter of 2025, an increase of 4.4%.
2026 Annual Guidance
The Company is updating its guidance for full-year 2026 revenue to $3.09 billion from the previous range of $3.18 billion to $3.22 billion, representing 5.1% revenue growth as compared to fiscal 2025. The Company reaffirms its full-year fiscal 2026 non-GAAP fully diluted EPS guidance to be in the range of $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully diluted EPS.
Conference Call Information
Globus Medical will hold a teleconference to discuss its 2026 third quarter results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news-events/events-webcasts.
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, merger and acquisition related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, and gains and losses from strategic investments, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represent the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, legal and tax fees for legal entity reorganization and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.
In addition, for the period ended September 30, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non-recurring tax adjustments, and the tax effects of all of the foregoing adjustments. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present non-GAAP adjusted gross profit, which excludes the impacts of any inventory acquisition-related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends.
Additionally, for the period ended September 30, 2026 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates. We are also presenting base business sales and revenue growth, excluding the contribution from Nevro Corp. (“Nevro”), which we acquired in 2025. We believe these provide insight to how the Company is performing without the impact of the Nevro acquisition.
Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP adjusted gross profit, free cash flow, constant currency net sales growth, base business revenue growth, and day-adjusted basis sales are not calculated in conformity with GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of these non-GAAP measures may differ from that of other companies and therefore may not be comparable. The tables included in this release reconcile the GAAP financial measures to the non-GAAP financial measures discussed above for the three and nine months ended September 30, 2026 and 2025.
We are unable to present a quantitative reconciliation of our expected fully diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of provision for litigation, amortization of intangibles, merger and acquisition-related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, certain income tax net benefits from non-recurring tax adjustments, gains and losses from strategic investments, and the tax effects of all of the foregoing adjustments. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Income.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company,” “Globus,” “Globus Medical,” “we,” “us,” and “our” refers to Globus Medical, Inc.
Share Repurchase Program
On November 2, 2026, our Board of Directors authorized the Company to repurchase an additional $500 million of shares of its common stock under our existing share repurchase program (the “Repurchase Program”), which does not have an expiration date. Repurchases under the Repurchase Program may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and actual number of shares repurchased under the Repurchase Program will be determined by management at its discretion and will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements and alternative investment opportunities. The Repurchase Program has no time limit and may be suspended for periods or discontinued at any time.
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands, except per share amounts) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net sales | $ | 763,719 | $ | 769,048 | $ | 2,313,185 | $ | 2,112,511 | |||||||||||||||
| Cost of sales and operating expenses: | |||||||||||||||||||||||
| Cost of sales (exclusive of amortization of intangibles) | 232,917 | 252,533 | 708,422 | 696,695 | |||||||||||||||||||
| Research and development | 34,529 | 38,067 | 107,360 | 111,083 | |||||||||||||||||||
| Selling, general and administrative | 288,471 | 313,597 | 873,069 | 860,018 | |||||||||||||||||||
| Amortization of intangibles | 29,574 | 29,843 | 88,660 | 88,834 | |||||||||||||||||||
| Acquisition-related costs | 720 | (2,713) | 18,177 | 31,500 | |||||||||||||||||||
| Restructuring costs | (43) | 358 | 7,126 | 13,905 | |||||||||||||||||||
| Operating income/(loss) | 177,551 | 137,363 | 510,371 | 310,476 | |||||||||||||||||||
| Other income/(expense), net | |||||||||||||||||||||||
| Interest income/(expense), net | 8,413 | 1,455 | 20,921 | 3,829 | |||||||||||||||||||
| Foreign currency transaction gain/(loss) | (1,714) | (161) | (4,687) | 4,147 | |||||||||||||||||||
| Bargain purchase gain | — | 3,800 | 1,118 | 114,361 | |||||||||||||||||||
| Other income/(expense) | (982) | 1,537 | 2,436 | 3,022 | |||||||||||||||||||
| Total other income/(expense), net | 5,717 | 6,631 | 19,788 | 125,359 | |||||||||||||||||||
| Income/(loss) before income taxes | 183,268 | 143,994 | 530,159 | 435,835 | |||||||||||||||||||
| Income tax provision/(benefit) | 42,097 | 25,028 | 113,117 | 38,561 | |||||||||||||||||||
| Net income/(loss) | $ | 141,171 | $ | 118,966 | $ | 417,042 | $ | 397,274 | |||||||||||||||
| Other comprehensive income/(loss), net of tax: | |||||||||||||||||||||||
| Unrealized gain/(loss) on marketable securities | (2,074) | 30 | (3,785) | 347 | |||||||||||||||||||
| Foreign currency translation gain/(loss) | 2,214 | 658 | (225) | 17,441 | |||||||||||||||||||
| Total other comprehensive income/(loss), net of tax | 140 | 688 | (4,010) | 17,788 | |||||||||||||||||||
| Comprehensive income/(loss) | $ | 141,311 | $ | 119,654 | $ | 413,032 | $ | 415,062 | |||||||||||||||
| Earnings per share: | |||||||||||||||||||||||
| Basic | $ | 1.05 | $ | 0.88 | $ | 3.09 | $ | 2.93 | |||||||||||||||
| Diluted | $ | 1.04 | $ | 0.88 | $ | 3.04 | $ | 2.90 | |||||||||||||||
| Weighted average shares outstanding: | |||||||||||||||||||||||
| Basic | 134,150 | 134,502 | 134,853 | 135,484 | |||||||||||||||||||
| Diluted | 136,017 | 135,394 | 137,195 | 137,219 | |||||||||||||||||||
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)
| September 30, | December 31, | ||||||||||
| (In thousands, except share and per share values) | 2026 | 2025 | |||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 441,272 | $ | 526,156 | |||||||
| Short-term marketable securities | 76,163 | 31,087 | |||||||||
Accounts receivable, net of allowances $47,866 and $33,434, respectively | 675,297 | 678,938 | |||||||||
| Inventories | 824,144 | 759,277 | |||||||||
| Prepaid expenses and other current assets | 116,437 | 65,426 | |||||||||
| Income taxes receivable | 48,651 | 64,727 | |||||||||
| Total current assets | 2,181,964 | 2,125,611 | |||||||||
| Property and equipment, net | 532,760 | 564,452 | |||||||||
| Operating lease right of use assets | 56,768 | 63,786 | |||||||||
| Long-term marketable securities | 353,738 | 71,819 | |||||||||
| Intangible assets, net | 667,468 | 745,064 | |||||||||
| Goodwill | 1,453,561 | 1,435,033 | |||||||||
| Other assets | 75,993 | 78,781 | |||||||||
| Deferred income taxes | 205,941 | 218,215 | |||||||||
| Total assets | $ | 5,528,193 | $ | 5,302,761 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 107,428 | $ | 98,852 | |||||||
| Accrued expenses | 326,858 | 333,586 | |||||||||
| Operating lease liabilities | 14,176 | 14,738 | |||||||||
| Income taxes payable | 5,844 | 4,155 | |||||||||
| Business acquisition liabilities | 25,820 | 19,513 | |||||||||
| Deferred revenue | 27,812 | 27,655 | |||||||||
| Total current liabilities | 507,938 | 498,499 | |||||||||
| Business acquisition liabilities, net of current portion | 80,547 | 81,995 | |||||||||
| Operating lease liabilities | 93,378 | 103,918 | |||||||||
| Deferred income taxes and other tax liabilities | 31,603 | 23,756 | |||||||||
| Other liabilities | 18,477 | 21,343 | |||||||||
| Total liabilities | 731,943 | 729,511 | |||||||||
| Equity: | |||||||||||
Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 110,235,170 and 112,625,126 shares at September 30, 2026 and December 31, 2025, respectively | 110 | 113 | |||||||||
Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 and 22,430,097 shares at September 30, 2026 and December 31, 2025, respectively | 22 | 22 | |||||||||
| Additional paid-in capital | 3,259,292 | 3,169,812 | |||||||||
| Accumulated other comprehensive income/(loss) | 11,336 | 15,346 | |||||||||
| Retained earnings | 1,525,490 | 1,387,957 | |||||||||
| Total equity | 4,796,250 | 4,573,250 | |||||||||
| Total liabilities and equity | $ | 5,528,193 | $ | 5,302,761 | |||||||
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
| Nine Months Ended September 30, | |||||||||||
| (In thousands) | 2026 | 2025 | |||||||||
| Cash flows from operating activities: | |||||||||||
| Net income | $ | 417,042 | $ | 397,274 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Bargain purchase gain | (1,118) | (114,361) | |||||||||
| Depreciation and amortization | 209,730 | 207,357 | |||||||||
| Provision for excess and obsolete inventory | 14,671 | 15,988 | |||||||||
| Amortization of acquisition accounting fair value step up | — | 19,631 | |||||||||
| Stock-based compensation expense | 37,743 | 38,361 | |||||||||
| Allowance for expected credit losses | 13,954 | 5,311 | |||||||||
| Change in fair value of business acquisition liabilities | 16,231 | 2,668 | |||||||||
| Change in deferred income taxes | 24,778 | 525 | |||||||||
| (Gain)/loss on disposal of assets, net | 6,765 | 8,438 | |||||||||
| Payment of business acquisition-related liabilities | (2,965) | (16,425) | |||||||||
| Net (gain)/loss from foreign currency adjustment | 277 | (14,621) | |||||||||
| (Increase) decrease in: | |||||||||||
| Accounts receivable | (12,345) | 11,971 | |||||||||
| Inventories | (60,086) | (17,420) | |||||||||
| Prepaid expenses and other assets | 3,826 | (6,689) | |||||||||
| Increase (decrease) in: | |||||||||||
| Accounts payable | 6,664 | (654) | |||||||||
| Accrued expenses and other liabilities | (15,375) | 25,442 | |||||||||
| Income taxes payable/receivable | 17,540 | (57,936) | |||||||||
| Net cash provided by/(used in) operating activities | 677,332 | 504,860 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of marketable securities | (398,841) | (37,109) | |||||||||
| Sales and maturities of marketable securities | 66,805 | 174,238 | |||||||||
| Purchases of property and equipment | (113,172) | (118,482) | |||||||||
| Acquisition of businesses, net of cash acquired and purchases of intangible and other assets | (22,417) | (262,212) | |||||||||
| Net cash provided by/(used in) investing activities | (467,625) | (243,565) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Payment of business acquisition-related liabilities | (17,417) | (11,240) | |||||||||
| Net proceeds from exercise of stock options | 52,812 | 26,999 | |||||||||
| Payments related to tax withholdings for share-based compensation | (3,453) | (2,698) | |||||||||
| Repurchase of common stock | (279,001) | (255,451) | |||||||||
| Repayment of senior convertible notes | — | (449,985) | |||||||||
| Net cash provided by/(used in) financing activities | (247,059) | (692,375) | |||||||||
| Effect of foreign exchange rates on cash | (1,117) | 18,411 | |||||||||
| Net increase/(decrease) in cash, cash equivalents, and restricted cash | (38,469) | (412,669) | |||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 526,156 | 784,438 | |||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 487,687 | $ | 371,769 | |||||||
| Supplemental disclosures of cash flow information: | |||||||||||
| Income taxes paid, net | $ | 65,804 | $ | 95,096 | |||||||
| Non-cash investing and financing activities: | |||||||||||
| Accrued purchases of property and equipment | $ | 12,209 | $ | 13,454 | |||||||
The following table provides a reconciliation of cash and cash equivalents reported on our condensed consolidated balance sheets to the total of the cash, cash equivalents, and restricted cash reported within our condensed consolidated statements of cash flows.
| As of September 30, | |||||||||||
| (In thousands) | 2026 | 2025 | |||||||||
| Cash and cash equivalents shown in the condensed consolidated balance sheets | $ | 441,272 | $ | 371,769 | |||||||
| Restricted escrow deposits included in prepaid expenses and other current assets | 46,415 | — | |||||||||
| Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows | $ | 487,687 | $ | 371,769 | |||||||
Supplemental Financial Information
Net Sales by Product Category:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Musculoskeletal Solutions | $ | 728,855 | $ | 741,009 | $ | 2,225,379 | $ | 2,027,124 | |||||||||||||||
| Enabling Technologies | 34,864 | 28,039 | 87,806 | 85,387 | |||||||||||||||||||
| Total net sales | $ | 763,719 | $ | 769,048 | $ | 2,313,185 | $ | 2,112,511 | |||||||||||||||
Liquidity and Capital Resources:
| September 30, | December 31, | ||||||||||
| (In thousands) | 2026 | 2025 | |||||||||
| Cash and cash equivalents | $ | 441,272 | $ | 526,156 | |||||||
| Short-term marketable securities | 76,163 | 31,087 | |||||||||
| Long-term marketable securities | 353,738 | 71,819 | |||||||||
| Total cash, cash equivalents and marketable securities | $ | 871,173 | $ | 629,062 | |||||||
The following tables reconcile GAAP to non-GAAP financial measures.
Non-GAAP Adjusted EBITDA Reconciliation Table:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands, except percentages) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net income/(loss) | $ | 141,171 | $ | 118,966 | $ | 417,042 | $ | 397,274 | |||||||||||||||
| Interest (income)/expense, net | (8,413) | (1,455) | (20,921) | (3,829) | |||||||||||||||||||
| Provision for income taxes | 42,097 | 25,028 | 113,117 | 38,561 | |||||||||||||||||||
| Depreciation and amortization | 70,933 | 71,126 | 211,138 | 207,831 | |||||||||||||||||||
| EBITDA | 245,788 | 213,665 | 720,376 | 639,837 | |||||||||||||||||||
| Stock-based compensation expense | 11,743 | 11,528 | 37,740 | 37,838 | |||||||||||||||||||
| Provision for litigation, net | 3,665 | 28,261 | 3,861 | 24,353 | |||||||||||||||||||
Merger and acquisition-related costs (1) | 632 | 4,678 | 18,363 | 46,177 | |||||||||||||||||||
| Net (gain) loss from strategic investments | 911 | (946) | (278) | (2,255) | |||||||||||||||||||
| Non-cash acquisition-related foreign currency impacts | (60) | (3,045) | (277) | (15,382) | |||||||||||||||||||
| Restructuring costs | (473) | 2,260 | 8,674 | 22,909 | |||||||||||||||||||
| Bargain purchase gain | — | (3,800) | (1,118) | (114,361) | |||||||||||||||||||
| Adjusted EBITDA | $ | 262,206 | $ | 252,601 | $ | 787,341 | $ | 639,116 | |||||||||||||||
| Net income/(loss) as a percentage of net sales | 18.5 % | 15.5 % | 18.0 % | 18.8 % | |||||||||||||||||||
| Adjusted EBITDA as a percentage of net sales | 34.3 % | 32.8 % | 34.0 % | 30.3 % | |||||||||||||||||||
(1)Merger and acquisition-related costs represent certain costs associated with acquisitions. These costs, presented on a before-tax effect basis, are included in Non-GAAP Merger and Acquisition-related Costs Table.
Non-GAAP Merger and Acquisition-related Costs Table:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Amortization of inventory fair value step up | $ | — | $ | 6,957 | $ | — | $ | 12,973 | |||||||||||||||
| Change in fair value of business acquisition liabilities | 172 | (2,721) | 16,231 | 2,681 | |||||||||||||||||||
Employee-related costs (b) | 548 | — | 1,946 | 27,418 | |||||||||||||||||||
Other acquisition-related costs (a) | (88) | 442 | 186 | 3,105 | |||||||||||||||||||
| Merger and acquisition-related costs | $ | 632 | $ | 4,678 | $ | 18,363 | $ | 46,177 | |||||||||||||||
(a)Primarily comprised of legal fees, advisory and consulting fees.
(b)Primarily comprised of severance, share-based compensation and termination fees.
Non-GAAP Net Income Reconciliation Table:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net income/(loss) | $ | 141,171 | $ | 118,966 | $ | 417,042 | $ | 397,274 | |||||||||||||||
| Provision for litigation, net | 3,665 | 28,261 | 3,861 | 24,353 | |||||||||||||||||||
| Amortization of intangibles | 29,574 | 29,843 | 88,660 | 88,834 | |||||||||||||||||||
Merger and acquisition-related costs (1) | 632 | 4,678 | 18,363 | 46,177 | |||||||||||||||||||
| Net gain/(loss) on strategic investments | 911 | (946) | (278) | (2,255) | |||||||||||||||||||
| Non-cash acquisition-related foreign currency impacts | (60) | (3,045) | (277) | (15,382) | |||||||||||||||||||
| Restructuring costs | (473) | 2,260 | 8,674 | 22,909 | |||||||||||||||||||
| Bargain purchase gain | — | (3,800) | (1,118) | (114,361) | |||||||||||||||||||
| Provision for income tax benefit from non-recurring tax adjustments | — | (1,740) | — | (36,555) | |||||||||||||||||||
| Tax effect of adjusting items | (8,378) | (15,127) | (28,695) | (40,034) | |||||||||||||||||||
| Non-GAAP net income/(loss) | $ | 167,042 | $ | 159,350 | $ | 506,232 | $ | 370,960 | |||||||||||||||
(1)See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table for the detail of these costs.
Non-GAAP Gross Profit Reconciliation Table:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands, except percentages) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net sales | $ | 763,719 | $ | 769,048 | $ | 2,313,185 | $ | 2,112,511 | |||||||||||||||
| Cost of sales (exclusive of amortization of intangibles) | 232,917 | 252,533 | 708,422 | 696,695 | |||||||||||||||||||
| Amortization of intangibles | 21,651 | 22,665 | 63,872 | 69,516 | |||||||||||||||||||
| Gross Profit | $ | 509,151 | $ | 493,850 | $ | 1,540,891 | $ | 1,346,300 | |||||||||||||||
| Amortization of inventory fair value step up | — | 6,957 | — | 12,973 | |||||||||||||||||||
| Amortization of intangibles | 21,651 | 22,665 | 63,872 | 69,516 | |||||||||||||||||||
| Adjusted Gross Profit | $ | 530,802 | $ | 523,472 | $ | 1,604,763 | $ | 1,428,789 | |||||||||||||||
| Gross Profit % of Net Sales | 66.7 % | 64.2 % | 66.6 % | 63.7 % | |||||||||||||||||||
| Adjusted Gross Profit % of Net Sales | 69.5 % | 68.1 % | 69.4 % | 67.6 % | |||||||||||||||||||
Non-GAAP Diluted Earnings Per Share Reconciliation Table:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (Per share amounts) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Diluted earnings per share, as reported | $ | 1.04 | $ | 0.88 | $ | 3.04 | $ | 2.90 | |||||||||||||||
| Provision for litigation, net | 0.03 | 0.21 | 0.03 | 0.18 | |||||||||||||||||||
| Amortization of intangibles | 0.22 | 0.22 | 0.65 | 0.65 | |||||||||||||||||||
Merger and acquisition-related costs (1) | — | 0.03 | 0.13 | 0.34 | |||||||||||||||||||
| Net (gain) loss from strategic investments | 0.01 | (0.01) | — | (0.02) | |||||||||||||||||||
| Non-cash acquisition-related foreign currency impacts | — | (0.02) | — | (0.11) | |||||||||||||||||||
| Restructuring costs | — | 0.02 | 0.06 | 0.17 | |||||||||||||||||||
| Bargain purchase gain | — | (0.03) | (0.01) | (0.83) | |||||||||||||||||||
| Provision for income tax benefit from non-recurring tax adjustments | — | (0.01) | — | (0.27) | |||||||||||||||||||
| Tax effect of adjusting items | (0.06) | (0.11) | (0.21) | (0.29) | |||||||||||||||||||
| Non-GAAP diluted earnings per share | $ | 1.23 | $ | 1.18 | $ | 3.69 | $ | 2.70 | |||||||||||||||
(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail of these costs.
*Amounts may not add due to rounding.
Non-GAAP Free Cash Flow Reconciliation Table:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net cash provided by operating activities | $ | 265,227 | $ | 249,696 | $ | 677,332 | $ | 504,860 | |||||||||||||||
| Purchases of property and equipment | (40,389) | (35,817) | (113,172) | (118,482) | |||||||||||||||||||
| Free cash flow | $ | 224,838 | $ | 213,879 | $ | 564,160 | $ | 386,378 | |||||||||||||||
Non-GAAP Net Sales on a Constant Currency Basis Comparative Table:
| Three Months Ended September 30, | Reported Net Sales Growth | Currency Impact on Current Period Net Sales | Constant Currency Net Sales Growth | ||||||||||||||||||||||||||
| (In thousands, except percentages) | 2026 | 2025 | |||||||||||||||||||||||||||
| United States | $ | 620,980 | $ | 617,633 | 0.5% | $ | — | 0.5% | |||||||||||||||||||||
| International | 142,739 | 151,415 | (5.7%) | (1,124) | (5.0%) | ||||||||||||||||||||||||
| Total net sales | $ | 763,719 | $ | 769,048 | (0.7%) | $ | (1,124) | (0.5%) | |||||||||||||||||||||
| Nine Months Ended September 30, | Reported Net Sales Growth | Currency Impact on Current Period Net Sales | Constant Currency Net Sales Growth | ||||||||||||||||||||||||||
| (In thousands, except percentages) | 2026 | 2025 | |||||||||||||||||||||||||||
| United States | $ | 1,844,973 | $ | 1,702,274 | 8.4% | $ | — | 8.4% | |||||||||||||||||||||
| International | 468,212 | 410,237 | 14.1% | 10,430 | 11.6% | ||||||||||||||||||||||||
| Total net sales | $ | 2,313,185 | $ | 2,112,511 | 9.5% | $ | 10,430 | 9.0% | |||||||||||||||||||||
Base Business and Nevro Corp. Net Sales Reconciliation Table:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (In thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net Sales of Nevro products | $ | 73,701 | $ | 99,254 | $ | 237,392 | $ | 193,839 | |||||||||||||||
| Net Sales of base business | 690,018 | 669,794 | 2,075,793 | 1,918,671 | |||||||||||||||||||
| Total net sales | $ | 763,719 | $ | 769,048 | $ | 2,313,185 | $ | 2,112,511 | |||||||||||||||
Investor Contact:
Shagun Singh
Senior Vice President, Strategy and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com